journal article·2021-10

Bacterial-based cancer therapy: An emerging toolbox for targeted drug/gene delivery

Dewu Lin, Xiaolan Feng, Bingjie Mai, Xin Li, Fei Wang, Jiexi Liu, Xin Liu, Kun Zhang, Xiaobing Wang

Biomaterials· Volume 277
Publisher page

Abstract

Precise targeting and high therapeutic efficiency are the major requisites of personalized cancer treatment. However, some unique features of the tumor microenvironment (TME) such as hypoxia, low pH and elevated interstitial fluid pressure cause cancer cells resistant to most therapies. Bacteria are increasingly being considered for targeted tumor therapy owing to their intrinsic tumor tropism, high motility as well as the ability to rapidly colonize in the favorable TME. Compared to other nano-strategies using peptides, aptamers, and other biomolecules, tumor-targeting bacteria are largely unaffected by the tumor cells and microenvironment. On the contrary, the hypoxic TME is highly conducive to the growth of facultative anaerobes and obligate anaerobes. Live bacteria can be further integrated with anti-cancer drugs and nanomaterials to increase the latter's targeted delivery and accumulation in the tumors. Furthermore, anaerobic and facultatively anaerobic bacteria have also been combined with other anti-cancer therapies to enhance therapeutic effects. In this review, we have summarized the applications and advantages of using bacteria for targeted tumor therapy (Scheme 1) in order to aid in the design of novel intelligent drug delivery systems. The current challenges and future prospects of tumor-targeting bacterial nanocarriers have also been discussed.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Cancer Research and Treatments · Nanoplatforms for cancer theranostics · 3D Printing in Biomedical Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Nanoparticle delivery of cancer drugs10.1146/annurev-med-040210-162544 ↗
2. Nanocarriers for cancer-targeted drug delivery10.3109/1061186X.2015.1051049 ↗
3. Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment10.1039/C6CS00592F ↗
4. Engineered nanoparticles for drug delivery in cancer therapy10.1002/anie.201403036 ↗
5. Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles10.1016/j.biomaterials.2011.04.078 ↗
6. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications10.1016/j.jconrel.2014.12.030 ↗
7. Hydrophobic blocks of PEG-conjugates play a significant role in the accelerated blood clearance (ABC) phenomenon10.1016/j.jconrel.2012.11.016 ↗
8. Analysis of nanoparticle delivery to tumours10.1038/natrevmats.2016.14 ↗
9. Reengineering the tumor microenvironment to alleviate hypoxia and overcome cancer heterogeneity10.1101/cshperspect.a027094 ↗
10. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges10.1038/nrclinonc.2018.29 ↗
11. Bacteria-inspired nanomedicine10.1021/acsabm.0c01072 ↗
12. Quorum-sensing Salmonella selectively trigger protein expression within tumors10.1073/pnas.1414558112 ↗
13. Optically-controlled bacterial metabolite for cancer therapy10.1038/s41467-018-03233-9 ↗
14. Bacteria-Driven hypoxia targeting for combined biotherapy and photothermal therapy10.1021/acsnano.8b02235 ↗
15. Nanophotosensitizer-engineered Salmonella bacteria with hypoxia targeting and photothermal-assisted mutual bioaccumulation for solid tumor therapy10.1016/j.biomaterials.2019.119226 ↗
16. Spontaneous regression of tumour and the role of microbial infection-possibilities for cancer treatment10.1097/CAD.0000000000000337 ↗
17. Salmonella-mediated cancer therapy: roles and potential10.1007/s13139-016-0415-z ↗
18. Solid tumors provide niche-specific conditions that lead to preferential growth of Salmonella10.18632/oncotarget.9071 ↗
19. Combination bacteriolytic therapy for the treatment of experimental tumors10.1073/pnas.251543698 ↗
20. Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice10.1016/j.ijmm.2007.01.008 ↗
21. A microfluidic device for studying chemotaxis mechanism of bacterial cancer targeting10.1038/s41598-018-24748-7 ↗
22. Salmonella typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis10.1158/0008-5472.CAN-06-2618 ↗
23. Containment of tumor-colonizing bacteria by host neutrophils10.1158/0008-5472.CAN-07-2984 ↗
24. Influence of infection route and virulence factors on colonization of solid tumors by Salmonella enterica serovar Typhimurium10.1111/j.1574-695X.2011.00790.x ↗
25. Bacterial therapy of cancer: promises, limitations, and insights for future directions10.3389/fmicb.2018.00016 ↗
26. Tumors Salmonella migrate away from vasculature toward the transition zone and induce apoptosis10.1038/cgt.2011.10 ↗
27. Motility is critical for effective distribution and accumulation of bacteria in tumor tissue10.1039/c2ib00091a ↗
28. Tumour-targeting bacteria engineered to fight cancer10.1038/s41568-018-0070-z ↗
29. Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression10.1038/s41467-020-16967-2 ↗
30. Rewritable multi-event analog recording in bacterial and mammalian cells10.1126/science.aap8992 ↗
31. Bacteria-cancer interactions: bacteria-based cancer therapy10.1038/s12276-019-0297-0 ↗
32. Genetically engineered oncolytic bacteria as drug delivery systems for targeted cancer theranostics10.1016/j.actbio.2021.02.006 ↗
33. Salmonella induce autophagy in melanoma by the downregulation of AKT/mTOR pathway10.1038/gt.2013.86 ↗
34. Salmonella as an innovative therapeutic antitumor agent10.3390/ijms150814546 ↗
35. Anticancer activity of bacterial proteins and peptides10.3390/pharmaceutics10020054 ↗
36. Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies10.2174/138161209788923949 ↗
37. Anticancer effects of the microbiome and its products10.1038/nrmicro.2017.44 ↗
38. Targeted diphtheria toxin-based therapy: a review article10.3389/fmicb.2019.02340 ↗
39. Bacterial toxins for cancer therapy10.3390/toxins9080236 ↗
40. Claudins overexpression in ovarian cancer: potential targets for Clostridium Perfringens Enterotoxin (CPE) based diagnosis and therapy10.3390/ijms140510412 ↗
41. Botulinum toxin potentiates cancer radiotherapy and chemotherapy10.1158/1078-0432.CCR-05-1222 ↗
42. In vivo IFN-γ secretion by NK cells in response to Salmonella typhimurium requires NLRC4 inflammasomes10.1371/journal.pone.0097418 ↗
43. Activation of inflammasome by attenuated Salmonella typhimurium in bacteria-mediated cancer therapy10.1111/1348-0421.12333 ↗
44. Salmonella-mediated cytolethal distending toxin transfer inhibits tumor growth10.1089/hum.2018.030 ↗
45. CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients10.1007/s00262-004-0546-4 ↗
46. Pseudomonas aeruginosa exotoxin T induces potent cytotoxicity against a variety of murine and human cancer cell lines10.1099/jmm.0.000003 ↗
47. Effect of Clostridium perfringens enterotoxin on gastric cancer cells SGC7901 which highly expressed claudin-4 protein10.4251/wjgo.v9.i4.153 ↗
48. Claudin-4-targeted therapy using Clostridium perfringens enterotoxin for prostate cancer10.1002/pros.21436 ↗
49. Cancer immunotherapy based on killing of Salmonella-infected tumor cells10.1158/0008-5472.CAN-04-3002 ↗
50. Flagellin enhances tumor-specific CD8⁺ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model10.1016/j.vaccine.2013.06.054 ↗
51. Bacteria-induced gap junctions in tumors favor antigen cross-presentation and antitumor immunity10.1126/scitranslmed.3000739 ↗
52. Therapeutic benefit of Salmonella attributed to LPS and TNF-α is exhaustible and dictated by tumor susceptibility10.18632/oncotarget.16906 ↗
53. Salmonella typhimurium suppresses tumor growth via the pro-inflammatory cytokine interleukin-1β10.7150/thno.11432 ↗
54. Salmonella enhance chemosensitivity in tumor through connexin 43 upregulation10.1002/ijc.28155 ↗
55. Induction of CD4(+) and CD8(+) anti-tumor effector T cell responses by bacteria mediated tumor therapy10.1002/ijc.29567 ↗
56. Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies10.1126/scitranslmed.aax0876 ↗
57. The inhibition of indoleamine 2, 3-dioxygenase 1 by connexin 4310.7150/ijms.20661 ↗
58. Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy10.1186/2051-1426-1-15 ↗
59. Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer10.1158/2326-6066.CIR-13-0058 ↗
60. Salmonella overcomes tumor immune tolerance by inhibition of tumor indoleamine 2, 3-dioxygenase 1 expression10.18632/oncotarget.6258 ↗
61. Gene therapy using bacterial vectors10.2741/4473 ↗
62. Genetically engineered Salmonella Typhimurium: recent advances in cancer therapy10.1016/j.canlet.2019.01.037 ↗
63. Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent10.1089/104303402320139005 ↗
64. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients10.1038/sj.cgt.7700634 ↗
65. Carboxypeptidase-G2-based gene-directed enzyme-prodrug therapy: a new weapon in the GDEPT armoury10.1038/nrc2247 ↗
66. Bacteria-mediated tumor therapy utilizing photothermally-controlled TNF-α expression via oral administration10.1021/acs.nanolett.7b05323 ↗
67. Bacterial delivery of a novel cytolysin to hypoxic areas of solid tumors10.1038/gt.2008.188 ↗
68. Potent anti-tumor activity of systemically-administered IL2-expressing Salmonella correlates with decreased angiogenesis and enhanced tumor apoptosis10.1016/j.clim.2008.08.021 ↗
69. Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth10.1007/s00262-008-0555-9 ↗
70. Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin10.1126/scitranslmed.aak9537 ↗
71. PD-1-siRNA delivered by attenuated Salmonella enhances the antimelanoma effect of pimozide10.1038/s41419-019-1418-3 ↗
72. Endostatin gene therapy delivered by attenuated Salmonella typhimurium in murine tumor models10.1038/s41417-018-0021-6 ↗
73. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth10.1038/nm1202-794 ↗
74. Spores of Clostridium engineered for clinical efficacy and safety cause regression and cure of tumors in vivo10.18632/oncotarget.1761 ↗
75. Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy10.1158/1078-0432.CCR-07-4800 ↗
76. Tumor-targeting prodrug-activating bacteria for cancer therapy10.1038/cgt.2008.10 ↗
77. Antitumor effect of cytosine deaminase/5-fluorocytosine suicide gene therapy system mediated by Bifidobacterium infantis on melanoma10.1111/j.1745-7254.2005.00094.x ↗
78. Engineered commensal microbes for diet-mediated colorectal-cancer chemoprevention10.1038/s41551-017-0181-y ↗
79. Genetically engineered Salmonella typhimurium as an imageable therapeutic probe for cancer10.1158/0008-5472.CAN-09-3453 ↗
80. Engineering of bacteria for the visualization of targeted delivery of a cytolytic anticancer agent10.1038/mt.2013.183 ↗
81. Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice10.1038/sj.bjc.6605403 ↗
82. Antitumor therapeutic effects of a genetically engineered Salmonella typhimurium harboring TNF-α in mice10.1007/s00253-010-3006-4 ↗
83. Salmonella typhimurium mediated delivery of Apoptin in human laryngeal cancer10.7150/ijms.6960 ↗
84. Live attenuated Salmonella as a vector for oral cytokine gene therapy in melanoma10.1002/jgm.1023 ↗
85. Application of genetically engineered Salmonella typhimurium for interferon-gamma-induced therapy against melanoma10.1016/j.ejca.2016.10.010 ↗
86. Clostridium sporogenes delivers interleukin-12 to hypoxic tumours, producing antitumour activity without significant toxicity10.1111/lam.12322 ↗
87. Plasmid-based Survivin shRNA and GRIM-19 carried by attenuated Salmonella suppresses tumor cell growth10.1038/aja.2011.179 ↗
88. Systemic delivery of Salmonella typhimurium transformed with Ido shRNA enhances intratumoral vector colonization and suppresses tumor growth10.1158/0008-5472.CAN-12-0193 ↗
89. Enhanced therapeutic effect of cisplatin on the prostate cancer in tumor-bearing mice by transfecting the attenuated Salmonella carrying a plasmid co-expressing p53 gene and mdm2 siRNA10.1016/j.canlet.2013.05.028 ↗
90. Intratumoral delivery and suppression of prostate tumor growth by attenuated Salmonella enterica serovar typhimurium carrying plasmid-based small interfering RNAs10.1158/0008-5472.CAN-07-0098 ↗
91. Using attenuated Salmonella typhi as tumor targeting vector for MDR1 siRNA delivery10.4161/cbt.6.4.3850 ↗
92. CD8 T-cell induction against vascular endothelial growth factor receptor 2 by Salmonella for vaccination purposes against a murine melanoma10.1371/journal.pone.0034214 ↗
93. Antitumor effects of Stat3-siRNA and endostatin combined therapies, delivered by attenuated Salmonella, on orthotopically implanted hepatocarcinoma10.1007/s00262-012-1256-y ↗
94. Doxorubicin-conjugated Escherichia coli Nissle 1917 swimmers to achieve tumor targeting and responsive drug release10.1016/j.jconrel.2017.10.041 ↗
95. Nanoscale bacteria-enabled autonomous drug delivery system (NanoBEADS) enhances intratumoral transport of nanomedicine10.1002/advs.201801309 ↗
96. Bacterial microbots for acid-labile release of hybrid micelles to promote the synergistic antitumor efficacy10.1016/j.actbio.2018.07.041 ↗
97. Magneto-aerotactic bacteria deliver drug-containing nanoliposomes to tumour hypoxic regions10.1038/nnano.2016.137 ↗
98. Autonomous bacterial nanoswimmers target cancer10.1016/j.jconrel.2016.10.006 ↗
99. Active tumor-therapeutic liposomal bacteriobot combining a drug (paclitaxel)-encapsulated liposome with targeting bacteria (salmonella typhimurium)10.1016/j.snb.2015.09.034 ↗
100. Minicells deliver lethal load to tumours10.1038/nrd2366 ↗